US4728512A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Formulations providing three distinct releases
Assignee: Wyeth LLC
•
Filing: 1986-03-04
•
Granted: 1988-03-01
•
Expires: 2006-03-04
Abstract
Abstract A therapeutic preparation consisting of three groups of spheroids containing an active medicinal substance. The first group of spheroids is uncoated and rapidly disintegrates upon ingestion to release an initial dose of medicinal substance a second group of spheroids is coated with a pH sensitive coat to provide a second dose and a third group of spheroids is coated with a pH independent coat to provide a third dose. A powder blend of active medicinal substance may be substituted for the first group of uncoated spheroids. The therapeutic preparation may be utilized as a mixture of groups of spheroids in a capsule.
Inventors
- 👤 Atul M. Mehta
- 👤 Lizbeth A. Bachand
- 👤 Thomas W. Leonard
- 👤 Ronald N. Warner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 23:03
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5084; A61K9/5073
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
253 words
A therapeutic composition for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing a powder blend of an active medicinal substance subject to extensive presystemic metabolism and two groups of coated spheroids each also containing such active medicinal substance, wherein (a) said powder blend comprises 10% to 50% by weight of active medicinal substance in admixture with pharmaceutical excipients for immediate release of active medicinal substance to provide a loading dose of such substance, (b) said first group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 20% to 75% by weight of active medicinal substance in admixture with non-water swellable cellulose, said film coating comprising (i) a copolymer based on methacrylic acid and methacrylic acid methyl ester or (ii) polyvinyl acetate phthalate, said first group of film coated spheroids having a pH sensitive coating to provide a delayed second dose of such substance and (c) said second group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copoylmer based on polymethacrylic acid esters containing metallic stearates, said second group of film coated spheroids being double coated with an effective thickness to provide a further delayed third dose of such substance.
Claim 2
Dependent Claim
253 words
A therapeutic composition for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing a powder blend of an active medicinal substance subject to extensive presystemic metabolism and two groups of coated spheroids each also containing such active medicinal substance, wherein (a) said powder blend comprises 10% to 50% by weight of active medicinal substance in admixture with pharmaceutical excipients for immediate release of active medicinal substance to provide a loading dose of such substance, (b) said first group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 20% to 75% by weight of active medicinal substance in admixture with non-water swellable cellulose, said film coating comprising (i) a copolymer based on methacrylic acid and methacrylic acid methyl ester or (ii) polyvinyl acetate phthalate, said first group of film coated spheroids having a pH sensitive coating to provide a delayed second dose of such substance and (c) said second group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copoylmer based on polymethacrylic acid esters containing metallic stearates, said second group of film coated spheroids being double coated with an effective thickness to provide a further delayed third dose of such substance.
Claim 3
Dependent Claim
246 words
A therapeutic composition for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing three groups of spheroids each containing an active medicinal substance subject to extensive presystemic metabolism wherein (a) said first group of spheroids comprises 10% to 50% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose for immediate release of active medicinal substance to provide a loading dose of such substance, (b) said second group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of active medicinal substance in admixture with non-water swellable cellulose, said film coating comprising (i) a copolymer based on methacrylic acid and methacryclic acid methyl ester or (ii) polyvinyl acetate phthalate, said first group of film coated spheroids having a pH sensitive coating to provide a delayed second dose of such substance, and (c) said third group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 40% to 65% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copolymer based on polymethacrylic acid esters containing metallic stearates, said second group of film coated spheroids being double coated with an effective thickness to provide a further delayed third dose of such substance.
Claim 4
Dependent Claim
246 words
A therapeutic composition for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing three groups of spheroids each containing an active medicinal substance subject to extensive presystemic metabolism wherein (a) said first group of spheroids comprises 10% to 50% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose for immediate release of active medicinal substance to provide a loading dose of such substance, (b) said second group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of active medicinal substance in admixture with non-water swellable cellulose, said film coating comprising (i) a copolymer based on methacrylic acid and methacryclic acid methyl ester or (ii) polyvinyl acetate phthalate, said first group of film coated spheroids having a pH sensitive coating to provide a delayed second dose of such substance, and (c) said third group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 40% to 65% by weight of active medicinal substance in admixture with non-water swellable microcrystalline cellulose and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copolymer based on polymethacrylic acid esters containing metallic stearates, said second group of film coated spheroids being double coated with an effective thickness to provide a further delayed third dose of such substance.
Claim 5
Dependent Claim
156 words
A therapeutic composition according to claim 2 comprising a pharmaceutical hard gelatin capsule containing three groups of spheroids containing an active medicinal substance, wherein (a) said first group of spheroids comprising uncoated spheroids contains medicinal substance for maximum release thereof within a period of two hours after ingestion, (b) said second group of spheroids contains medicinal substance coated with a pH sensitive coat comprising (i) a copolymer based on methacrylic acid and methacrylic acid methyl ester or (ii) polyvinyl acetate phthalate, said coat having an effective thickness to provide a maximum release of medicinal substance in a period of 2 to 6 hours after ingestion, and (c) said third group of spheroids contains medicinal substance coated with an undercoat of hydroxypropyl methylcellulose and an overcoat of the copolymer based on polymethacrylic acid esters containing metallic stearates, said coats having an effective thickness to provide a maximum release of medicinal substance 4 to 10 hours after ingestion.
Claim 6
Dependent Claim
122 words
A therapeutic composition according to claims 1 or 2 wherein said gelatin capsule contains a total of from 60 mg to 240 mg propranolol hydrochloride, wherein (a) said first group of spheroids or powder blend contains 10% to 30% of the total dose of propranolol hydrochloride, (b) said second group of spheroids contains 20% to 75% of the total dose of propranolol hydrochloride and said spheroids are coated with a copolymer based on methacrylic acid and methacrylic acid methyl ester and triacetin, and (c) said third group of spheroids contains 10% to 60% of the toral dose of propranolol hydrochloride and said spheroids are coated with an undercoat of hydroxypropyl methylcellulose and an overcoat of a copolymer based on polymethacrylic acid esters.
Claim 7
Dependent Claim
113 words
A therapeutic composition according to claim 4 wherein said gelatin capsule contains a total of 160 mg propranolol hydrochloride, wherein (a) said first group of spheroids contains 12% to 20% of the total dose of propranolol hydrochloride, (b) said second group of spheroids contains 35% to 45% of the total dose of propranolol hydrochloride and said spheroids are coated with the copolymer based on methacrylic acid and methacrylic acid methyl ester and triacetin, and (c) said third group of spheroids contains 35% to 45% of the total dose of propranolol hydrochloride and said spheroids are coated with an undercoat of hydroxypropyl methylcellulose and an overcoat of a copolymer based on polymethacrylic acid esters.
Claim 8
Dependent Claim
85 words
A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of an active medicinal substance in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) and overcoat consisting of a copolymer based on polymethacrylic acid esters containing metalic stearates.
Claim 9
Dependent Claim
85 words
A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of an active medicinal substance in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) and overcoat consisting of a copolymer based on polymethacrylic acid esters containing metalic stearates.
Claim 10
Dependent Claim
112 words
A therapeutic composition according to claim 6 for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of an active medicinal substance in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copolymer based on polymethacrylic acid esters containing metalic stearates, said coats having an effective thickness to provide a maximum release of medicinal substance 4 to 10 hours after ingestion.
Claim 11
Dependent Claim
183 words
A therapeutic composition according to claim 3 comprising a pharmaceutical hard gelatin capsule containing three groups of spheroids containing an active medicinal substance, wherein (a) said first group of spheroids comprising uncoated spheroids contains medicinal substance for maximum release thereof within a period of two hours after ingestion, (b) said second group of spheroids contains medicinal substance coated with a pH sensitive coat comprising 5% to 15% by weight of uncoated spheroids of (i) a copolymer based on methacrylic acid and methacrylic acid methyl ester or (ii) polyvinyl acetate phthalate, said coat having an effective thickness to provide a maximum release of medicinal substance in a period of 2 to 6 hours after ingestion, and (c) said third group of spheroids contains medicinal substance coated with an undercoat of 2.5% to 5.5% by weight of uncoated spheroids of hydroxypropyl methylcellulose and an overcoat of 5% to 12% by weight of uncoated spheroids of the copolymer based on polymethacrylic acid esters containing metallic stearates, said coats having an effective thickness to provide a maximum release of medicinal substance 4 to 10 hours after ingestion.
Claim 12
Dependent Claim
148 words
A therapeutic composition according to claims 1 or 2 wherein said gelatin capsule contains a total of from 60 mg to 240 mg propranolol hydrochloride, wherein (a) said first group of spheroids or powder blend contains 10% to 30% of the total dose of propranolol hydrochloride, (b) said second group of spheroids contains 20% to 75% of the total dose of propranolol hydrochloride and said spheroids are coated with 5% to 15% by weight of uncoated spheroids of a copolymer based on methacrylic acid and methacrylic acid methyl ester and triacetin, and said third group of spheroids contains 10% to 60% of the total dose of propranolol hydrochloride and said spheroids are coated with an undercoat of 2.5% to 5.5% by weight of uncoated spheroids of hydroxypropyl methylcellulose and an overcoat of 5% to 15% by weight of uncoated spheroids of a copolymer based on polymethacrylic acid esters.
References Cited (Backward Citations)
US2809918A
Cited
US2921883A
Cited
US3175521A
Cited
US3119742A
Cited
GB1204580A
Cited
US3835221A
Cited
US3859431A
Cited
US4138475A
Cited
US4173626A
Cited
GB2039737A
Cited
US4248856A
Cited
US4309406A
Cited
US4248857A
Cited
US4248858A
Cited
US4309404A
Cited
US4309405A
Cited
US4294819A
Cited
US4339428A
Cited
US4524060A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-03-01 | 1991-08-31 | 1992-03-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-03-01 | 1995-08-31 | 1996-03-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-03-01 | 1999-08-31 | 2000-03-01 | $7700.00 | Window Closed / Lapsed |